Envestnet Asset Management Inc. Reduces Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Envestnet Asset Management Inc. reduced its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,483,493 shares of the company’s stock after selling 45,894 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $19,196,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TAK. Capital Research Global Investors raised its stake in shares of Takeda Pharmaceutical by 3.6% in the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after purchasing an additional 503,446 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in Takeda Pharmaceutical by 47.9% during the 1st quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after buying an additional 3,912,569 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after acquiring an additional 356,069 shares in the last quarter. OLD Mission Capital LLC increased its holdings in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after acquiring an additional 973,935 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Takeda Pharmaceutical by 1.7% during the fourth quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock worth $11,053,000 after purchasing an additional 12,756 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.7 %

TAK stock opened at $14.91 on Tuesday. The firm has a market cap of $47.19 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.06. The firm has a fifty day moving average price of $14.35 and a two-hundred day moving average price of $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The firm had revenue of $7.75 billion for the quarter. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.